Previous 10 | Next 10 |
Zymeworks (NYSE:ZYME), a clinical-stage biotech focused on cancer therapeutics announced the appointment of biotech veteran Paul Moore as its new Chief Scientific Officer effective next month. Dr. Moore is expected to join Zymeworks (ZYME) on July 18, the company said, adding that he will bri...
Dr. Moore will lead Zymeworks’ Early Research & Development Group responsible for advancing the Company’s next-generation of multispecific antibody programs and antibody drug conjugate (ADC) programs into clinical studies Zymeworks Inc. (NYSE: ZYME), a ...
The following slide deck was published by Zymeworks Inc. in conjunction with this event. For further details see: Zymeworks (ZYME) Presents At Jefferies Healthcare Conference - Slideshow
The board of clinical-stage biopharmaceutical company Zymeworks (NYSE:ZYME) adopted a limited-duration shareholder rights plan, intending to enable shareholders to realize the full value of their investment. The moves comes in the wake of an unsolicited, non-binding proposal by All Blue Falco...
Plan ensures shareholders are protected and treated equitably Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical compa...
Avadel Pharmaceuticals (AVDL) +39%. Solo Brands (DTC) +14%. PMV Pharmaceuticals (PMVP) +15% on early data for lead asset in solid tumors. Red Robin Gourmet Burgers (RRGB) +13% on Q1 earnings release. DiDi Global (DIDI) +11% on report of China's FAW interest ...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: Jefferies Healthcare Conference . Zymeworks will participate...
Update 5:20pm: Updates shares, adds new data ahead of ASCO conference. Zymeworks (NYSE:ZYME) rose 4% in after hours trading after investment firm All Blue Falcons raised its stake in the oncology oncology maker after its $10.50/share offer was rejected last Friday. The com...
Study of zanidatamab in combination with docetaxel results in 90.5% confirmed objective response rate (cORR) in first-line treatment of advanced HER2-positive breast cancer Zanidatamab in combination with chemotherapy and tislelizumab shows 75.8% cORR and 100% diseas...
Zymeworks (NYSE:ZYME) rose 2% in after hours trading after investment firm All Blue Falcons raised its stake in the oncology oncology maker after its $10.50/share offer was rejected last Friday. All Blue Falcons boosted its stake to 6.9% and now owns just under 4m shares a...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...